This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.
Histologically and/or cytologically documented local advanced or recurrent or metastatic malignancies.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Expected survival >3 months.
Signed informed consent form.
Any remaining AEs > grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss and fatigue.
Pregnant or nursing women or women/men who are ready to give birth.
symptomatic central nervous system metastasis.
Allergy to other antibody drugs or any excipients in the study drugs.